Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects
Abstract The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism in vivo, since a specific assay syst...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.14469 |
| _version_ | 1818152506532823040 |
|---|---|
| author | Yasutaka Takeda Yukihiro Fujita Tsuyoshi Yanagimachi Nobuhiro Maruyama Ryoichi Bessho Hidemitsu Sakagami Jun Honjo Hiroki Yokoyama Masakazu Haneda |
| author_facet | Yasutaka Takeda Yukihiro Fujita Tsuyoshi Yanagimachi Nobuhiro Maruyama Ryoichi Bessho Hidemitsu Sakagami Jun Honjo Hiroki Yokoyama Masakazu Haneda |
| author_sort | Yasutaka Takeda |
| collection | DOAJ |
| description | Abstract The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism in vivo, since a specific assay system for GIP (1–30) has not yet been established. We first developed a sandwich enzyme‐linked immunosorbent assay (ELISA) specific for GIP (1–30) by combining a novel antibody specific to the GIP (1–30) C terminus with the common antibody against GIP N terminus. Then, we explored cross‐reactivities with incretins and glucagon‐related peptides in this ELISA. GIP (1–30) amide, but not GIP (1–42), GLP‐1, or glucagon increased absorbance in a dose‐dependent manner. We next measured plasma GIP (1–30) concentrations in nondiabetic participants (ND) during a 75‐g oral glucose tolerance test or cookie meal test (carbohydrates 75 g, lipids 28.5 g, proteins 8.5 g). Both glucose and cookie load increased GIP (1–30) concentrations in ND, but the increases were much lower than those of GIP (1–42). Furthermore, the DPP‐4 inhibitor significantly increased GIP (1–30) concentrations similarly to GIP (1–42) in ND. In conclusion, we for the first time developed an ELISA specific for GIP (1–30) and revealed its secretion in ND. |
| first_indexed | 2024-12-11T13:55:48Z |
| format | Article |
| id | doaj.art-b7f797beea1445df873c63d45e036208 |
| institution | Directory Open Access Journal |
| issn | 2051-817X |
| language | English |
| last_indexed | 2024-12-11T13:55:48Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Physiological Reports |
| spelling | doaj.art-b7f797beea1445df873c63d45e0362082022-12-22T01:04:03ZengWileyPhysiological Reports2051-817X2020-06-01811n/an/a10.14814/phy2.14469Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjectsYasutaka Takeda0Yukihiro Fujita1Tsuyoshi Yanagimachi2Nobuhiro Maruyama3Ryoichi Bessho4Hidemitsu Sakagami5Jun Honjo6Hiroki Yokoyama7Masakazu Haneda8Division of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanImmuno‐Biological Laboratories Co., Ltd. Fujioka JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanJiyugaoka Medical Clinic, Internal Medicine Obihiro JapanDivision of Metabolism and Biosystemic Science Department of Internal Medicine Asahikawa Medical University Asahikawa JapanAbstract The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism in vivo, since a specific assay system for GIP (1–30) has not yet been established. We first developed a sandwich enzyme‐linked immunosorbent assay (ELISA) specific for GIP (1–30) by combining a novel antibody specific to the GIP (1–30) C terminus with the common antibody against GIP N terminus. Then, we explored cross‐reactivities with incretins and glucagon‐related peptides in this ELISA. GIP (1–30) amide, but not GIP (1–42), GLP‐1, or glucagon increased absorbance in a dose‐dependent manner. We next measured plasma GIP (1–30) concentrations in nondiabetic participants (ND) during a 75‐g oral glucose tolerance test or cookie meal test (carbohydrates 75 g, lipids 28.5 g, proteins 8.5 g). Both glucose and cookie load increased GIP (1–30) concentrations in ND, but the increases were much lower than those of GIP (1–42). Furthermore, the DPP‐4 inhibitor significantly increased GIP (1–30) concentrations similarly to GIP (1–42) in ND. In conclusion, we for the first time developed an ELISA specific for GIP (1–30) and revealed its secretion in ND.https://doi.org/10.14814/phy2.14469cookie meal testDPP‐4 inhibitorELISAGIP (1–30)oral glucose tolerance test |
| spellingShingle | Yasutaka Takeda Yukihiro Fujita Tsuyoshi Yanagimachi Nobuhiro Maruyama Ryoichi Bessho Hidemitsu Sakagami Jun Honjo Hiroki Yokoyama Masakazu Haneda Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects Physiological Reports cookie meal test DPP‐4 inhibitor ELISA GIP (1–30) oral glucose tolerance test |
| title | Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| title_full | Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| title_fullStr | Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| title_full_unstemmed | Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| title_short | Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| title_sort | establishment of novel specific assay for short form glucose dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects |
| topic | cookie meal test DPP‐4 inhibitor ELISA GIP (1–30) oral glucose tolerance test |
| url | https://doi.org/10.14814/phy2.14469 |
| work_keys_str_mv | AT yasutakatakeda establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT yukihirofujita establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT tsuyoshiyanagimachi establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT nobuhiromaruyama establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT ryoichibessho establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT hidemitsusakagami establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT junhonjo establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT hirokiyokoyama establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects AT masakazuhaneda establishmentofnovelspecificassayforshortformglucosedependentinsulinotropicpolypeptideandevaluationofitssecretioninnondiabeticsubjects |